Page 29 - Product Testing News Today

Press release content from Business Wire. The AP news staff was not involved in its creation. PhaseBio Reports Fourth-Quarter and Full-Year 2020 Financial Results and Recent Business Highlights March 15, 2021 GMT MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--Mar 15, 2021-- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today reported financial results for the...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Phase 3 trial of Libtayo® (cemiplimab) monotherapy in advanced cervical cancer stopped early ... SanofiMarch 15, 2021 GMT Phase 3 trial of Libtayo® (cemiplimab) monotherapy in advanced cervical cancer stopped early for positive result on overall survival                                                                         �...

Press release content from KISSPR. The AP news staff was not involved in its creation.

Press release content from Business Wire. The AP news staff was not involved in its creation. Newron and Zambon Sign Agreement for Potentially Pivotal Study with safinamide in Parkinson’s Disease Patients March 15, 2021 GMT MILAN--(BUSINESS WIRE)--Mar 15, 2021-- Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system and its partner, Z...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and ... Tonix Pharmaceuticals Holding Corp.March 15, 2021 GMT Announced Positive Phase 3 RELIEF Study Results for TNX-102 SL 5.6 mg in Fibromyalgia Interim Analysis Results from Second Confirmatory Phase 3 Study, RALLY, Expected in Third Quarter 2021: Interim Cohort Enrolled Efficacy Data from Animal Studies of COVID-19 ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Shattuck Labs Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business ... Shattuck Labs, Inc.March 15, 2021 GMT – Initial dose-escalation data from Phase 1 clinical trial for lead wholly owned CD47 checkpoint inhibitor, SL-172154 (SIRPα-Fc-CD40L), expected in the second half of 2021 – – Dose-escalation data from Phase 1 clinical trial for lead partnered PD-1 checkpoint i...

Press release content from Business Wire. The AP news staff was not involved in its creation. PharmaEssentia Provides U.S. Regulatory Update on Ropeginterferon alfa-2b-njft for the Treatment of Polycythemia Vera (PV) March 14, 2021 GMT BURLINGTON, Mass.--(BUSINESS WIRE)--Mar 14, 2021-- PharmaEssentia Corporation (TPEx: 6446), a global biopharmaceutical innovator leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced that t...

Press release content from Business Wire. The AP news staff was not involved in its creation. Global Meningococcal Vaccines Disease Forecast and Market Analysis Report 2021-2024 - ResearchAndMarkets.com March 11, 2021 GMT DUBLIN--(BUSINESS WIRE)--Mar 11, 2021-- Market growth will be driven by the uptake of pentavalent vaccines, which could significantly boost coverage for the MenB component by linking the higher coverage rates observed with the booster dose of MenACWY in adolescents (53.7% in 2...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Bioventus Reports First Patients Enrolled in Phase 1 Clinical Trial of MOTYS™ (PTP-001) for the ... Bioventus, Inc.March 11, 2021 GMT DURHAM, N.C., March 11, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a leader in solutions for innovative healing, reported that the first patients have been enrolled and dosed in its Phase 1 open-label, dose-escalatio...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.